Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Wound Management Technologies, Inc. (OTC Bulletin Board:  WNDM) announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® .  In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.  

Cathy Bradshaw, President of Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc, said, "We are excited about the number of new clinicians using CellerateRx®.   This has also resulted in an increase in the number of new distributors of our product around the country."

"The physicians that have contacted me have experienced outstanding clinical efficacy, particularly on diabetic and arterial ulcers when using CellerateRx®," states Dr. Larry Baratta, VP of Medical Affairs for Wound Care Innovations.  "They also commented on the reduction of pain as noted by their patients with arterial ulcers while achieving wound resolution."

CellerateRx® is a patented, one of a kind collagen product that is FDA approved for market for all acute and chronic wounds except 3rd degree burns.  It successfully addresses the multi-billion dollar wound care market.